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Introduction
Metfrmin is a hiuanide that was reintroduccd in the United States
in I 995 to treat patients with Type 2 diabetes mellitus, It effeetivel\
results in reductions in lasting and postprandial blood glucose
concentrations and eN cos lated hemoglobin le’ els, primarily h\
decrcasiie hepatic gluci 5c production n addition. met l’ormin
acts to lower blood glucose cone entrations b\ improvin” insulin
scnsiti itv and decreasing intestinal absorption of glucose. The drug
may offer other potential henetits_ such as producing weight loss or
nunimi/ing weight gain in obese patients.
Its most common side etTects are gastrointestinal such as diarrhea.
d spepsia, nausea and anorexia. Lactic acidosis may also occur. hut
it is rare if metformin is avoided in patients with contraindications
to its use. Therefore, ineiformin is contraindicated in patients with
renal insuflIciency (patients with serum creatinine l .5 mg/dL
(males). l ,4 mg/dL d’einales) or abnormal creatinine clearance).
congestive heart failure requiring pharmacologic therapy and acute
or chronic metabolic acidosis. Hypoglcemia does not occur under
usual circumstances. hut could occur when caloric intake is deficient
01 during conconlitant usc ss ith other glucose lowering agents.
[tlderl\ .dcbilitatcd or malnourished pitmei1ts. and those with adrenal
or pituitary insut’fieienc or alcohol intosication are partictilarl\
‘LIsceptible to hvpogh ceuimc eflects.
\lctforinin-induced weight loss 15 found to he a desirable citect in
ohee patients with T pe 2 diabetes mellitus. I—low ever, execssm\ C
\\ eight loss in elderl patiems with Type 2 diabetes mellitus ma he
underreported and unrecognized. We report three eases of metformi n
induced weight loss and anorexia that prompted evaluation for
occult malignancy. In each case, anorexia and weight loss were
res ersed with the discontinuation of mettdrmin,
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Case #1
.\n t) ear-olil (itinese female was diagnosed with 11 pe 2 diabetes
mnellitus eight ears prior to presentation. She was placed on
met formi ii 59)) mc dai lv and gI ipi z ide 5 mc daily tw o \ears later.
She presented with niarked anorexia and a ten pound ss eight los”
oscr ix months i 11th to 99 lh. She denied earl satiet\ . but
complained ol an inability to appreciate tast\ loods. On exam. she
weighed 99 potitids with a height of 5’ 1.5” (BMI= ISv She Lmnder—
went extensis e gastrointestinal e altiation to exclude a visceral
malignancy ,An abdominal CT revealed fatty infiltration oft[ie liver
and no other abnormalities. An upper GI series with small bowel
follow through as well as a malahsorption evaluation were
unrevealing. Thyroid function studies were normal. She was
referred for endocrine consultation. \letlormin was discontinued,
and her appetite was restored to normal within one month. She
regained nine pounds live months alter discontinuation ol ineit rin in.
Case #2
A 79 ear—old Chinese female with T\ pe 2 diabetes nlellitus on
metformin 1 tJt)tt mc tw ice daily presented with a 42 pound weight
loss) 128 to 86 lb over two years. She complained ol anore\ia. but
denied nausea. omiting or diarrhea. On exam, she weighed 86
pounds and measured 5’2.5” in height (BMI= 1 5.7 m. An
esophogogastroseopy demonstrated no gastric malignancy. At that
time, her glyeosylated hemoglobin was 6.6ff and TSR level normal
at 0,95 uU/mL 0.24—3.80). She was referred for endocrine
evaluation. Mettormin was discontinued, and her weight increased
to 99 pounds seven months later. I low ever, her gl eos kited
hemoglobin also increased to 8. 1 d 50 she w as started m chimepmride
1.5 me qd.
Case #3
A 70 year—old Japanese male with Parkinson’s disease was diag
nosed with T\ pe 2 diahetes mdl itus I is e \ cams prior to pmesenlatioim
and started on metforniin 500mg tw ice dail\. (dlipiiide 2)1 mug dailr
was added two months prior to presentation. Re presented with
anorexia. generalized weakness and a progressive 44 pound weight
loss (190 to 146 lb over five years. Re was hospitalized for fis e days
to exclude a gastrointestinal malignancy. Abdominal CT scan was
unremarkable, and upper endoseopy only revealed mild y’astritis.
Colonoseopy denionstrated diverticuli and small polyps, II is TSR
level was normal at I .26 uLT/mL 0.24’ 3.8(9. ()n exam. lie weighed
49 lhsnd mueaured 51” n height BMI=25 . His metfornun was
discontinued, and hi” appetite ieturned. lie uhce’quentl i’egaimiei.l
21; punsli in one seair Fittcen months aLter discontinuation 01
nictlornimn. lie weighed 169 pounds. I-loss ever, one year later his
104
course was complicated by aspiration pneumonia. He currently
requires tube keJtng. md his ss eieht is 43 pounds.
Discussion
Metlonnin—i nduced sxeigln loss in obese uhtects is ss elI doeu
mented. in the I ah5 Pedersen et al, swdied ‘es en hospitalized
obese ss oniert and found a 2V greater ayeraL’e weight reduction
during periods in which metfortnin was given in addition to dietary
caloric restriction, More reeentl, most studies shoss a modest
weight loss between 23 kg during the hrst year of treatment with
metformin. This effect has been observed in nondiahetic5 and
diahetie° obese sublects. 324 obese suhiects were randomized to
metformin or placebo for one year, and compared ss ith placebo,
mettormin induced a significant sseight loss (20 kg vs. 0. kg). A
study of obese ss omen on caloric restricted diets ss ith and without
polc stie ovarian ‘\ndrome randomized to metformin ?5() nic hid
or placebo slioss ed that alter si \ months. metformin reduced body
weiuht and b dy niass indes to a significaittly greater degree than
placebo
In 1995. Stuinsoll etal. ‘tudred obese fype 2diahetic subjects and
tound that netformin 255() ire dark tor 1 2 ss eeks produced a 3 k
weight loss. This sseight loss ss as largely accounted for b loss of
adipose tissue. The mechanism for weight loss is uncertain, hut it
is proposed that increased thermogenic activity of brown adipose
tissue arid reduction in adipose mass or increased “futile” cycling of
substrates are two possibilities. in addition, studies of obese
women with Type 2 diabetes meilitus indicate that metformin may
itiduce appetite suppression as demonstrated by signtficantiu lower
hunger ratings on metforminm compared to placebo. Caloric intake
appeared to decrease with ntet I oririr ii in a doe
depende ii t in an ii er.’
Although niodest xsemght loss secondary to
metformin in obese subjects is ss elI known, in
our reviess of the literature there is an absence
of documented se\ crc ss eight Ii tss induced by
mettormin stiff icietit to raise suspicion of an
occult malignancy. We believe this phenorm
enon is unrecognized or underreported by phv
sicians, The first two patients we report here
ss rL of noi in. I a lit prior to rh i m iistration ofinctk rmin Fhc
third patient reported ss is obese urior to the adnnni tratmon of
inertor miii ss irh a B’\hl it O. \ll thre ssere cider Is \sian patients
e suspect that the anor etic ette5rin addition to tire “metallic taste”
that mar otcur sx oh ineitornimn thimaps resulted in oiisrdei abl\
decreased calor K intake. I mnicians should bL ass are of the pi ik ntial
,nmomeetm5efLij or niettor nun, ss Inch mar ntrmn caJie\ra ot nialus,
nanC \ . espec aIls in the elder Is p t i, nt I his ass arc ss mas
‘ircums ent n I es aluation h m ( _ It mal ignanes P u nts
ithi is pi. Ii b tc_s ssho u t’ iett rnriri and c p u.n
Cs cr s ioht lo Inor e it a I h i des c a di u I
mt rs al h ore nd oin’ c n i dia n tit. t stint
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